Abstract

Introduction: Hispanic/Latinos are the largest ethnic minority in United States with significant cultural and racial heterogeneity. The recent cholesterol treatment guidelines are mainly based on estimates from non-Hispanic white and black cohorts. Aim: To estimate the proportion of US Hispanic adults potentially affected by recent changes in recommendations for statin therapy eligibility under the 3rd National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP III) and the new 2013 ACC/AHA cholesterol treatment guidelines. Methods: HCHS/SOL is a large multi-center study of Hispanics/Latinos in US communities (Bronx, NY; Chicago, IL; Miami, FL; and San Diego, CA) (n=16,415; mean age 41 years, 40% males) . We evaluated weighted prevalence of statin-treated individuals and the proportion of target population that met the eligibility criteria for statin therapy under NCEP/ATP III versus 2013 ACC/AHA cholesterol treatment guidelines. Results: A total of 1,716 (10.4%) were treated with statins in HCHS/SOL cohort. However, 3,366 (20.5%) and 5,268 (32.1%) were eligible for statin therapy under NCEP/ATP III and 2013 ACC/AHA guidelines respectively. The proportion of statin-eligible adults increased primarily among older adults from 44% to 87% and males from 19% to 39% under NCEP/ATP III guidelines and 2013 ACC/AHA guidelines respectively (Figure 1). There was also an increase in eligibility for statin therapy in middle aged adults (44% to 65%). Conclusions: Regardless of the definition for statin eligibility, Hispanics are grossly undertreated (only half and only a third of those statin-eligible under the ATP III or the new ACC/AHA guidelines respectively are receiving treatment). The eligibility of statin therapy almost doubles consistently across all Hispanic/Latinos subgroups of under the new 2013 ACC/AHA guidelines.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.